| Study name |
Short‐/medium‐/long‐term outcomes |
Group 1 sample size |
Group 2 sample size |
Group 1 results
Mean (standard deviation)
|
Group 2 results
Mean (standard deviation)
|
Other data |
Notes |
| Arnold 2012a |
Short‐term mecamylamine (max 5 mg/day) |
12 |
8 |
−3.17 (8.76) |
−5.0 (10.78) |
"No significant differences were found for age, weight, sex, diagnosis, IQ, or entry scores for the OACIS, RBS, ABC Irritability, ABC Hyperactivity, ABC Lethargy/ Social Withdrawal, ABC Inappropriate Speech, ADI‐R Qualitative Abnormalities in Reciprocal Social Interaction or ADI‐R Qualitative Abnormalities in Communication" |
Skewed |
| Hollander 2020a |
Short‐term Trichuris suis ova (a dose of 2500 Trichurissuis ova every 2 weeks) |
10 |
10 |
−4.0 (18.5) |
−0.14 (6.32) |
P = 0.0687, 95% CI −4.82 to 91.32 |
Skewed |
| Minshawi 2016 |
Short‐term D‐cycloserine (50 mg once weekly) |
34 |
33 |
−1.55 (6.11) |
−1.23 (6.09) |
"teacher‐rated ABC data was returned for 23.5 % of the DCS group, and 30.3 % of the placebo group with no significant difference noted for any of the ABC subscales (irritability p = 0.623, social withdrawal p = 0.845" |
Skewed |
|
ABC: Aberrant Behaviour checklist; DCS: D‐cycloserine; OACIS: Ohio Autism Clinical Impressions Scale; RBS: Repetitive Behaviour Scale |
